Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 5 of 5
Full-Text Articles in Law
Is The Chemical Genus Claim Really “Dead” At The Federal Circuit?: Part Ii, Christopher M. Holman
Is The Chemical Genus Claim Really “Dead” At The Federal Circuit?: Part Ii, Christopher M. Holman
Faculty Works
A 2020 law review article entitled The Death of the Genus Claim (“Death”) purports to document a dramatic shift in the Federal Circuit’s interpretation of 35 U.S.C. 112(a)’s enablement and written description requirements, particularly as applied to chemical genus claims. According to the authors of Death, it has become nearly impossible to obtain a chemical genus claim that will be upheld as valid in the face of a challenge for overbreadth under Section 112(a). Death was cited extensively in Amgens’s successful petition for certiorari in Amgen v. Sanofi, a case asking the Supreme Court to overturn the Federal Circuit’s decision …
Covid-19: A Catalyst To Automate Protection Order Petitions To Support Self-Represented Litigants, Ayyoub Ajmi
Covid-19: A Catalyst To Automate Protection Order Petitions To Support Self-Represented Litigants, Ayyoub Ajmi
Faculty Works
COVID-19 exacerbated the crisis in access to legal services especially for victims of domestic violence for whom the pandemic made their situations even more precarious. In this article, the author shares his experience of building and implementing an automated solution to help pro-se litigants petition the court for emergency protection orders remotely and without the need to visit the courthouse. The article describes the lessons learned in developing a state court online portal dedicated to educating abuse victims and providing them with an automated way to petition the court for protection orders remotely without the need to visit a courthouse. …
Is The Chemical Genus Claim Really “Dead” At The Federal Circuit?: Part I, Christopher M. Holman
Is The Chemical Genus Claim Really “Dead” At The Federal Circuit?: Part I, Christopher M. Holman
Faculty Works
A 2020 law review article entitled The Death of the Genus Claim (“Death”) purports to document a dramatic shift in the Federal Circuit’s interpretation of 35 U.S.C. 112(a)’s enablement and written description requirements, particularly as applied to chemical genus claims. According to the authors of Death, it has become nearly impossible to obtain a chemical genus claim that will be upheld as valid in the face of a challenge for overbreadth under Section 112(a). Death was cited extensively in Amgens’s successful petition for certiorari in Amgen v. Sanofi, a case asking the Supreme Court to overturn the Federal Circuit’s decision …
Broken Infrastructure, Del C. Wright Jr.
Antibody Claims And The Evolution Of The Written Description/Enablement Requirement, S Sean Tu, Christopher M. Holman
Antibody Claims And The Evolution Of The Written Description/Enablement Requirement, S Sean Tu, Christopher M. Holman
Faculty Works
No abstract provided.